Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study
Journal of Clinical Apheresis · 2025
DOI: 10.1002/jca.70072 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Apheresis, 2025. Verfasst von Jameel Abdulrehman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Central Venous Catheters, Venous Thromboembolism, Rivaroxaban. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paul B. Helliwell Foundation.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Individuals with sickle cell disease (SCD) often require central venous catheter (CVC) use; however, this is associated with a high incidence of venous thromboembolism (VTE). We conducted a pilot randomized controlled trial (RCT) to assess if it is feasible and safe to conduct an adequately powered RCT comparing rivaroxaban to placebo as thromboprophylaxis in adult SCD participants with CVC. In this pilot investigator‐initiated, double‐blinded, multi‐center RCT, we assessed feasibility outcomes to explore if a full RCT is possible, and also exploratory outcomes of thrombosis and bleeding. THIS pilot trial was closed prematurely due to slow recruitment, lack of funding, and non‐feasibility of the complete trial. Of 21 participants who met eligibility criteria, 4 were recruited into the study. Adherence to study procedures was 100% and loss to follow‐up was 0%. One participant was noted to have a VTE during follow‐up, but of unknown chronicity. Another participant developed a new VTE post‐randomization, but prior to starting study drug. No major or clinically relevant bleeding events occurred during study follow‐up. Challenges in running the study were largely due to a limited eligible population, and low participation interest in study involvement. Trial Registration: ClinicalTrials.gov identifier: NCT05033314
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada.
- Division of Hematology, Department of Medicine, Centre Hospitalier de L'université de Montréal (CHUM), Montreal, Canada.
- Toronto General Hospital Research Institute, Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.
- Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.
- Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Canada.
ORCID-Profile: Jameel Abdulrehman, Stéphanie Forté, George Tomlinson, Ziad Solh, Lauren Bolster, Haowei Linda Sun, Kevin H M Kuo
Förderung
- Paul B. Helliwell Foundation
Zitieren
APA
Abdulrehman, J., Forté, S., Tomlinson, G., Solh, Z., Bolster, L., Sun, H. L., & Kuo, K. H. M. (2025). Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70072
Vancouver
Abdulrehman J, Forté S, Tomlinson G, Solh Z, Bolster L, Sun HL, et al. Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70072
BibTeX
@article{Abdulrehman2025,
author = {Abdulrehman, Jameel and Forté, Stéphanie and Tomlinson, George and Solh, Ziad and Bolster, Lauren and Sun, Haowei Linda and Kuo, Kevin H M},
title = {Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters ( THIS ) Pilot Study},
journal = {Journal of Clinical Apheresis},
year = {2025},
doi = {10.1002/jca.70072}
}
EUVIMED